#OTD# in 1982 laureate James Allison published a paper in the Journal of Immunology identifying the protein structure of the T cell receptor, a previously mysterious ignition switch for immune response. His research led to a new way to treat cancer by using our own immune systems.

ABBVIE $ABBV Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $17.40B (Est. $17.31B) 🟢; +10.3% YoY 🔹 Adj. EPS: $3.82 (Est. $3.75) 🟢; +100%+ YoY 🔹 Immunology Revenue: $9.17B; +16.3% YoY Raises FY26 Guide: 🔹 Adj. EPS: $13.95-$13.99 (Est. $13.92) 🟢; from $13.76-$13.96 Segment Net Revenue: 🔹 Immunology: $9.17B; +16.3% YoY 🔹 Neuroscience: $3.39B (Est. $3.29B) 🟢; +19.4% YoY 🔹 Oncology: $1.70B (Est. $1.68B) 🟢; +0.8% YoY 🔹 Aesthetics: $1.18B (Est. $1.20B) 🔴; -1.4% YoY Key Products: 🔹 Skyrizi: $5.78B (Est. $5.72B) 🟢; +22.7% YoY 🔹 Rinvoq: $2.71B (Est. $2.73B) 🔴; +23.9% YoY 🔹 Humira: $683M (Est. $695M) 🔴; -31.2% YoY 🔹 Venclexta: $803M (Est. $793M) 🟢; +10.7% YoY 🔹 Imbruvica: $522M (Est. $530M) 🔴; -26.1% YoY 🔹 Vraylar: $1.07B; +14.3% YoY Key Updates: 🔹 Apogee Therapeutics acquisition completed, deepening AbbVie’s immunology pipeline 🔹 IPR&D and milestones expense: $0.11/share unfavorable impact 🔹 Quarterly dividend raised to $1.82/share, payable February 16, 2027 Comments: 🔸 “Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.”

The Health Care sector has been shown to have the highest return rate above every other sector Here are the top performing Health Care ETFs so far in 2026: 🥇 $LABU Direxion Daily S&P Biotech Bull 3X ETF +88.66% 🟢 🥈 $ARKG ARK Genomic Revolution ETF +61.68% 🟢 🥉 $IDNA iShares Genomics Immunology and Healthcare ETF +52.09% 🟢 4. $XBI State Street SPDR S&P Biotech ETF +34.14% 🟢 5. $SBIO ALPS Medical Breakthroughs ETF +30.53% 🟢 6. $FBT First Trust NYSE Arca Biotechnology Index Fund +29.69% 🟢 7. $FTXH First Trust Nasdaq Pharmaceuticals ETF +26.86% 🟢 8. $BBH VanEck Biotech ETF +26.54% 🟢 9. $XPH State Street SPDR S&P Pharmaceuticals ETF +25.42% 🟢 10. $IBB iShares Biotechnology ETF +25.02% 🟢 11. $IHE iShares US Pharmaceuticals ETF +23.34% 🟢 12. $PJP Invesco Pharmaceuticals ETF +23.14% 🟢 13. $PTH Invesco Dorsey Wright Healthcare Momentum ETF +22.59% 🟢 14. $IHF iShares US Healthcare Providers ETF +20.27% 🟢 15. $PBE Invesco Biotechnology & Genome ETF +19.27% 🟢 16. $RSPH Invesco S&P 500 Equal Weight Health Care ETF +18.09% 🟢 17. $FXH First Trust Health Care AlphaDEX Fund +17.17% 🟢 18. $FHLC Fidelity MSCI Health Care Index ETF +12.66% 🟢 19. $PPH VanEck Pharmaceutical ETF +12.54% 🟢 20. $VHT Vanguard Health Care ETF +12.52% 🟢

AstraZeneca $AZN is launching a restructuring plan expected to generate $1.5B in annual savings, with up to $2B in one-time costs over the next three years. The company plans to reinvest those savings into its drug pipeline, which currently includes more than 180 projects. The move follows several late-stage clinical trial setbacks and growing competition from generic drugs. AstraZeneca is still targeting $80B in annual revenue and 20 new medicine launches by 2030. Meanwhile, Q3 revenue grew 7% to $16.21B, supported by double-digit growth in oncology, respiratory and immunology, and rare disease treatments.